Log In
Print
BCIQ
Print
Print this Print this
 

SAIT101

  Manage Alerts
Collapse Summary General Information
Company Samsung BioLogics
DescriptionBiosimilar of rituximab, a chimeric mAb against CD20 antigen
Molecular Target CD20
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat severe rheumatoid arthritis (RA)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today